Cargando…

Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors

Lymphocyte-specific protein tyrosine kinase (LCK) is common in a variety of hematologic malignancies but comparatively less common in solid tumors. This study aimed to explore the potential diagnostic and prognostic value of LCK across tumors through integrative and comprehensive pan-cancer analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Mingwei, Li, Yiming, Guo, Yixiao, Zhu, Wanwan, Jiang, Jianli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697346/ https://www.ncbi.nlm.nih.gov/pubmed/36430477 http://dx.doi.org/10.3390/ijms232213998

Ejemplares similares

SMURF2 facilitates ubiquitin-mediated degradation of ID2 to attenuate lung cancer cell proliferation
por: Han, Mingwei, et al.
Publicado: (2023)

Regulatory Mechanisms and Reversal of CD8(+)T Cell Exhaustion: A Literature Review
por: Zhu, Wanwan, et al.
Publicado: (2023)

A comprehensive analysis of the expression and regulation network of lymphocyte-specific protein tyrosine kinase in breast cancer
por: Meng, Yuhua, et al.
Publicado: (2021)

Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation
por: Rohrs, Jennifer A., et al.
Publicado: (2016)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors Target B Lymphocytes
por: Upfold, Nikki Lyn Esnardo, et al.
Publicado: (2023)

Comprehensive Analysis of the Prognostic and Immunological Role of PAFAH1B in Pan-Cancer
por: Yuan, Yixiao, et al.
Publicado: (2022)

A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation- regulated kinase 2 (DYRK2) in human tumors
por: Qiu, Xinyue, et al.
Publicado: (2022)

Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation
por: Weiße, Jonas, et al.
Publicado: (2021)

Correction: Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation
por: Weiße, Jonas, et al.
Publicado: (2023)

Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor
Publicado: (1996)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Integrative Analysis Reveals Comprehensive Altered Metabolic Genes Linking with Tumor Epigenetics Modification in Pan-Cancer
por: Shi, Yahui, et al.
Publicado: (2019)

Distinct intracellular localization of Lck and Fyn protein tyrosine kinases in human T lymphocytes
Publicado: (1994)

Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes
por: Hsueh, Robert C, et al.
Publicado: (2002)

Bruton’s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes
por: Sharif-Askari, Bahram, et al.
Publicado: (2019)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Barbarin, Alice, et al.
Publicado: (2020)

Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape
por: Zhang, Wei, et al.
Publicado: (2022)

Comprehensive translational control of tyrosine kinase expression by upstream open reading frames
por: Wethmar, K, et al.
Publicado: (2016)

The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells
por: Kagawa, Kozo, et al.
Publicado: (2022)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Predicting the Specificity- Determining Positions of Receptor Tyrosine Kinase Axl
por: Karakulak, Tülay, et al.
Publicado: (2021)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
por: Huang, Liling, et al.
Publicado: (2020)

Identification of a Fungi-Specific Lineage of Protein Kinases Closely Related to Tyrosine Kinases
por: Zhao, Zhongtao, et al.
Publicado: (2014)

An Integrative Pan-Cancer Analysis of PBK in Human Tumors
por: Wen, Huantao, et al.
Publicado: (2021)

Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression
por: Chen, Xi, et al.
Publicado: (2022)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

The Tyrosine Kinase p56(lck) Mediates Activation of Swelling-induced Chloride Channels in Lymphocytes
por: Lepple-Wienhues, Albrecht, et al.
Publicado: (1998)

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2015)

Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia
por: Benkisser-Petersen, Marco, et al.
Publicado: (2016)

Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
por: Dias, Ajoy Lawrence, et al.
Publicado: (2013)

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
por: Alkharabsheh, Omar, et al.
Publicado: (2021)

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
por: Eyre, Toby A., et al.
Publicado: (2023)

Checkpoint molecule PD-1-assisted CD8(+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Yao, Jiaxi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_57k0pin8etns5t8qtrq54osud9